Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links (clinical trials)

  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries

Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC) (CAT EEC Study)

Principal Investigator

Stephen Durham, MD | Imperial College London | London, UK
Piyush Patal, MD | Inflamax Research | Ontario, Canada

Locations

Inflamax Research, Inc | Ontario, Canada

Study Code

ITN061AD

Study Status

Completed

Abstract

The CAT EEC study, “Cat Pilot Study – Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC),” is being conducted at Inflamax Research, Inc. in Ontario, Canada and led by Drs. Stephen Durham (Imperial College London) and Piyush Patel (Inflamax Research, Inc.). The goal of the CAT EEC study is to directly compare allergic responses to cat by environmental exposure chamber vs. nasal allergen challenge to better understand and employ these methods as allergy evaluation tools in clinical trials.

Clinical trials of allergen immunotherapy frequently assess participants’ allergic status by challenging them with direct allergen delivery, such as via nasal spray, to measure corresponding clinical symptoms and other immunologic responses. Nasal allergen challenges are advantageous in that they can be replicated across multiple sites and enable controlled allergen doses, however they do not necessarily reflect real life ambient exposure. An alternative challenge method is via environmental exposure chambers, which are enclosed spaces that control temperature, air flow, and humidity and provide diffuse allergen exposure more closely simulating natural circumstances. 

CAT EEC is a single-site pilot study. After an initial dose-finding phase, 24 cat allergic adults will be randomly assigned to receive either nasal allergen challenge followed by environmental exposure chamber challenge (with a washout period in between), or environmental exposure chamber challenge followed by nasal allergen challenge. The study will measure clinical symptom scores and immunologic biomarkers to help inform endpoint selection for future ITN trials with aeroallergens.

About This Study

The CAT EEC study, “Cat Pilot Study – Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC),” is being conducted at Inflamax Research, Inc. in Ontario, Canada and led by Drs. Stephen Durham (Imperial College London) and Piyush Patel (Inflamax Research, Inc.). The goal of the CAT EEC study is to directly compare allergic responses to cat by environmental exposure chamber vs. nasal allergen challenge to better understand and employ these methods as allergy evaluation tools in clinical trials.

Clinical trials of allergen immunotherapy frequently assess participants’ allergic status by challenging them with direct allergen delivery, such as via nasal spray, to measure corresponding clinical symptoms and other immunologic responses. Nasal allergen challenges are advantageous in that they can be replicated across multiple sites and enable controlled allergen doses, however they do not necessarily reflect real life ambient exposure. An alternative challenge method is via environmental exposure chambers, which are enclosed spaces that control temperature, air flow, and humidity and provide diffuse allergen exposure more closely simulating natural circumstances. 

CAT EEC is a single-site pilot study. After an initial dose-finding phase, 24 cat allergic adults will be randomly assigned to receive either nasal allergen challenge followed by environmental exposure chamber challenge (with a washout period in between), or environmental exposure chamber challenge followed by nasal allergen challenge. The study will measure clinical symptom scores and immunologic biomarkers to help inform endpoint selection for future ITN trials with aeroallergens.

[Clinicaltrials.gov]

Do you Qualify for this Clinical Trial?

To learn more about this study and whether you are eligible to participate, please visit ClinicalTrials.gov.

Principal Investigator

Stephen Durham, MD | Imperial College London | London, UK
Piyush Patal, MD | Inflamax Research | Ontario, Canada

Locations

Inflamax Research, Inc | Ontario, Canada

Study Site Contact

Abbie Hillier            905-282-1808 or 1-888-989-1808           ahillier@inflamaxresearch.com

Articles

Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, Visness CM, Durham SR, Larson D, Esnault S, Ober C, Gergen PJ, Becker P, Togias A, Gern JE, Altman MC. (2020) Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2. J Allergy Clin Immunol, epub ahead of print. DOI: 10.1016/j.jaci.2020.04.009 PMID: 32333915 PMCID: PMC7175851 [PubMed] [Reprint]
Larson D, Patel P, Salapatek AM, Couroux P, Whitehouse D, Pina A, Johnson JL, Sever ML, Sanda S, Poyser J, Allio T, Scadding GW, Qin T, Shamji MH, Kwok WW, James E, French D, Lelic A, Larché M, Altman MC, Togias A, Durham SR. (2020) Nasal Allergen Challenge and Environmental Exposure Chamber Challenge: A Randomized Trial Comparing Clinical and Biological Responses to Cat Allergen. J Allergy Clin Immunol, 145 (6), 1585-1597. DOI: 10.1016/j.jaci.2020.02.024 PMID: 32169380 PMCID: PMC8958045 [PubMed] [Reprint]

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility